Buy Like Buffett
Watchlist

LEXARIA BIOSCIENCE CORP.

LEXX · Healthcare · $10.9M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

60

2023–2025 (latest 3 aligned FYs; v3 window cap 5): revenue $226208 to $705923, increasing; diluted EPS -0.51 to -0.66, decreasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.

70

Median gross margin 80.9% over 10y, variable.

0

Median ROIC -300.4%, above the 12% hurdle in 0% of years.

55

Net cash position — no leverage risk.

44

Owner earnings changed trend unclear over up to the ten most recent annual observations, share count n/a.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$0.56
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

17 years of fundamentals

The business, in plain English

LEXARIA BIOSCIENCE CORP. booked $705923 of revenue in FY2025 in the Healthcare sector and kept 99.6% of it as gross profit — a high-margin business by that measure. After every other cost, −1686.0% of each revenue dollar reached the bottom line.

It earned −790.3% on invested capital in the latest filed year, FY2025. Across the full 8-year measurable filed record, median ROIC was −300.4%. Over the v3 recent window (6 measurable filed years), median ROIC was −300.4%. The Returns on Capital filter above scores it 0/100.

LEXX's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the five filters (70/100) and Returns on Capital the weakest (0/100), which is how LEXX lands at 46/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2009–FY2025 · 17 fiscal years, normalized from LEXX’s SEC filings

Sales, as filed$705923 FY2025
$0$5000002009201520212025
Revenue kept after cost of goods99.6% FY2025
−100%0%100%2009201520212025
Standard ROIC or separately labeled Operating ROICROIC −790.3% FY2025
−500%0%2009201520212025
Cash an owner could take out−$11.9M FY2025
−$10M−$5M$02009201520212025

Gaps in a line mean that item isn’t in LEXX’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How LEXARIA BIOSCIENCE CORP. makes its money

LEXARIA BIOSCIENCE CORP.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:

Table alternative
Filed lineValue% of revenueSource
$705923100%
Cost of revenue$27200%
$703203100%
−$11.9M−1683%
Income before tax−$11.9M−1687%
−$11.9M−1686%
Source: · event Aug 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What LEXARIA BIOSCIENCE CORP. owns — and owes

LEXARIA BIOSCIENCE CORP.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$4.2M100%
Cash and equivalents$1.8M43%
Stockholders’ equity$3M72%
Source: · event Aug 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives LEXARIA BIOSCIENCE CORP.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−216%Tax burden100%net income ÷ pretax incomeInterest burden100%pretax ÷ operating incomeOperating margin−1683%operating income ÷ revenueAsset turnover0.11×revenue ÷ average assetsEquity multiplier1.18×average assets ÷ average equityAs of 2025-08-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$11.9MFY2025
Income before tax−$11.9MFY2025
Operating income−$11.9MFY2025
$705923FY2025
Ending assets$4.2MFY2025
Beginning assets$8.9MFY2024
$3MFY2025
$8MFY2024
Source:
  • SEC filingFiling detailsAccession 0001640334-24-001787
  • SEC filingFiling detailsAccession 0001640334-25-002225
· event Aug 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where LEXARIA BIOSCIENCE CORP.'s cash went

LEXARIA BIOSCIENCE CORP.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations−$10.5M−100%
Depreciation and amortization$512250%
Source: · event Aug 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding LEXARIA BIOSCIENCE CORP.

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 unavailable

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalUnavailableComparison unavailableFiling unavailable
Akre CapitalUnavailableComparison unavailableFiling unavailable
Baupost GroupUnavailableComparison unavailableFiling unavailable
Berkshire HathawayUnavailableComparison unavailableFiling unavailable
Brave Warrior AdvisorsUnavailableComparison unavailableFiling unavailable
Dodge & CoxUnavailableComparison unavailableFiling unavailable
First EagleUnavailableComparison unavailableFiling unavailable
FundsmithUnavailableComparison unavailableFiling unavailable
Gardner Russo & QuinnUnavailableComparison unavailableFiling unavailable
Gates Foundation TrustUnavailableComparison unavailableFiling unavailable
Mairs & PowerUnavailableComparison unavailableFiling unavailable
Markel / Markel-GaynerUnavailableComparison unavailableFiling unavailable
Oakmark / Harris AssociatesUnavailableComparison unavailableFiling unavailable
Pershing SquareUnavailableComparison unavailableFiling unavailable
Polen CapitalUnavailableComparison unavailableFiling unavailable
Sequoia / Ruane CunniffUnavailableComparison unavailableFiling unavailable
Southeastern Asset ManagementUnavailableComparison unavailableFiling unavailable
Tweedy, BrowneUnavailableComparison unavailableFiling unavailable
Yacktman Asset ManagementUnavailableComparison unavailableFiling unavailable

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source unavailable · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What LEXARIA BIOSCIENCE CORP. insiders reported

Records still being gathered — partial as of retrieval Aug 18, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

15 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale45.8 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Aug 18, 2026.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

No reported Form 4 rows were captured for LEXX; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.

A filing source-event date will appear when a Form 4 row is captured.

Retrieved .

Track record

How LEXARIA BIOSCIENCE CORP.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2011–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored LEXX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score2050100Indexed price · log scale (2021 = 100)201120142017202020232026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the reconstructed history shown, LEXX did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.

Healthcare context

#245 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #243PAHC Phibro Animal Health Corporation45.9Shallow moat
  2. #244COHR COHERENT CORP.45.8Shallow moat
  3. #246CTKB CYTEK BIOSCIENCES, INC.45.7Shallow moat
  4. #247CDIX Cardiff Lexington Corporation45.6Shallow moat

Compare LEXX with its nearest peers →All Healthcare companies on the Index →

Common questions about LEXX

Does LEXARIA BIOSCIENCE CORP. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores LEXARIA BIOSCIENCE CORP. (LEXX) 45.8 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 60, pricing power 70, returns on capital 0, balance-sheet safety 55, capital allocation 44.
How has LEXX's Moat Score changed over time?
The record logs 15 readings since Jul 17, 2026; the latest reads 45.8 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell LEXX. See the disclaimer.